The Oracle Speaks

Established February 2009

https://theoptionsoracle.com/

12 July 2015

Summary of Trades:

Closed Positions:

Sell to Open VTL Aug 2015 $15 Put @ Limit $6 GTC

Sell to Open XOMA Aug 2015 $3.5 Put @ Limit $1.00 GTC

VTL @ $25.82

Vital Therapies, Inc.

Sell to Open VTL Aug 2015 $15 Put @ Limit $6 GTC

Bid $6.10 / Time $6.20

40% return in 38 days

$10,000 should generate $4000.00

Vital Therapies, Inc., a biotherapeutic company, focuses on developing a cell-based therapy for the treatment of acute liver failure in the United States. Its ELAD system is an extracorporeal bio-artificial liver therapy that is in Phase III clinical trials to allow the patient’s own liver to regenerate to a healthy state, or to stabilize the patient until transplant. The company was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, Inc. in June 2003. Vital Therapies, Inc. was founded in 2003 and is headquartered in San Diego, California.

Vital Therapies, Inc.
15010 Avenue of Science
Suite 200
San Diego, CA 92128
Phone: 858-673-6840
Fax: 858-673-6843
Website: http://www.vitaltherapies.com

XOMA @ $4.72

XOMA Corporation

Sell to Open XOMA Aug 2015 $3.5 Put @ Limit $1.00 GTC

Bid $1.00 / Time $1.03

28.5% return in 38 days

$10,000 should generate $2850.00

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company’s lead product candidate includes gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçet’s disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, as well as diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis. Its proprietary product pipeline also comprises XOMA metabolic activating, sensitizing, and deactivating/antagonizing antibodies that are in preclinical stage for the treatment of diabetes patients; XOMA 3AB, a multi-antibody product for the treatment of human botulism poisoning; and XOMA 629, a topical anti-bacterial product for the treatment of human immune system. In addition, the company licenses antibody discovery, optimization, and development technologies, including Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX. It has collaboration and licensing agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Pfizer Inc.; Symplmed Pharmaceuticals, LLC; and Texas A&M University. The company was founded in 1981 and is headquartered in Berkeley, California.

XOMA Corporation
2910 Seventh Street
Berkeley, CA 94710
Phone: 510-204-7200
Website: http://www.xoma.com

news: http://finance.yahoo.com/news/xoma-receives-orphan-drug-designation-130000660.html

Orphan drug designation is granted by the FDA Office of Orphan Products Development (OOPD) to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the United States. The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity, as well as tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance, and waiver of Prescription Drug User Fee Act (PDUFA) filing fees. The OOPD also works on rare disease issues with the medical and research communities, professional organizations, academia, governmental agencies, industry, and rare disease patient groups

Company News

New toll free number:

1-866-466-4617

 

Free Webinar

Got a question or concern? Want to learn our philosophy, why it pays so well and so consistently?

Register today and watch your emails!

Please use the phone option for audio.

 

Auto Trading is now active!

Don’t want to be bothered doing the trades? Auto-trading is for you. Your account will automatically copycat our trades.

You are still in control, you set the limits either a dollar amount or a percentage.

Learn how to set up auto-trading here:

https://theoptionsoracle.com/auto-trading/

 

Like

"Like" us on Facebook

Follow

"Follow" us on Twitter

Quote of the Month:

“Someone’s sitting in the shade today because someone planted a tree a long time ago.” ~ Warren Buffet

Refer a Friend

The greatest compliment you can give us is to share The Options Oracle with your friends.

Military discounts available!

Contact The Options Oracle for details!

Your Name (required)

Your Email (required)

Your Phone Number (required)

Your Message

captcha

CAPTCHA Code

These are actual trades.

The Options Oracle does not tell you what to do, we are showing you what we are doing.

Your subscription fee may be 100% TAX DEDUCTIBLE if used for educational business/investment purposes. Check with your Licensed Professional adviser

Options involve risk and are not suitable for all investors. Prior to trading options, you must be approved for options trading and read the Characteristics and Risks of Standardized Options.

Copies of this document may also be obtained from your broker, from any exchange on which options are traded, by placing an order online, or by contacting the Options Clearing Corporation directly at 1 N. Wacker Dr., Suite 500, Chicago, IL 60606. (1-888-678-4667).

“The Options Oracle” does not manage money for any financial institution. You are purchasing the list of stocks that we use to select options contracts that we feel these options will return the highest, safest profits. We are not a broker or brokers, or a financial adviser. We have developed a successful strategy and are willing to share some of the information that has led to our success. We urge you to paper trade these picks and learn how to develop a strategy that is appropriate for you.

We make no recommendations on investment and we do not provide financial, tax or legal advice. Content and tools are provided for educational and informational purposes only.

Disclaimer

Trading or investment in stocks, futures & options, and commodity are subject to potential market risks. You can use our materials or recommendations for educational purposes, this is not intended as Trading or Investment advice. We are not financial advisers. We cannot provide any advice as to whether or not options or our trading ideas are suitable investments for your particular financial situation. We are in the business of publishing our trade ideas for market analysis only. We highly recommend that our subscribers review their trading allocation with a qualified registered financial adviser/planner.

Legal Disclaimer: we do not exist to render and do not give legal, tax, economic or investment advice and disclaims all liability for the actions or inaction taken or not as a result of communications from or to its members, officers, directors, employees and contractors. Each individual should consult his/her own counsel, accountant and other advisors as to legal, tax, economic, investment and related matters concerning any type of investments.

This email and any files transmitted with it are solely intended for the use of the addressee(s) and may contain information that is confidential and privileged. If you receive this email in error, please advise us by return email immediately. Please also disregard the contents of the email, delete it and destroy any copies immediately.